About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Clinical Updates in CLL and MCL
Clinical Updates in CLL and MCL
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Debate: Auto-HCT Remains the Preferred Standard of Care for 1L Therapy of MCL
By
19th Annual International Ultmann Chicago Lymphoma Symposium
FEATURING
Timothy Fenske
By
19th Annual International Ultmann Chicago Lymphoma Symposium
FEATURING
Timothy Fenske
291 views
July 8, 2022
0 Comments
Login to view comments.
Click here to Login
Clinical Updates in CLL and MCL
17:54
19th Annual International Ultmann Chicago Lymphoma Symposium
Debate: Auto-HCT Remains the Preferred Standard of Care for 1L Thera…
Feat.
T. Fenske
17:53
19th Annual International Ultmann Chicago Lymphoma Symposium
Sequencing of Therapies in R/R MCL
Feat.
K. Maddocks
06:32
ecancer
Primary Results of the Phase III SHINE Study: Ibrutinib in Combinati…
Feat.
M. Wang
04:51
ecancer
EHA 2022 on Targeted Therapy Combinations With Venetoclax Superior t…
Feat.
B. Eichhorst
04:29
ecancer
EHA 2022 Time-Limited Venetoclax-Obinutuzumab +/- Ibrutinib Surpasse…
Feat.
B. Eichhorst
05:39
ASCO 2022 Conference Coverage
ASCO 2022 Treatment Patterns and Real-World Effectiveness of Rituxim…
Feat.
M. Di
01:44
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 Treatment Patterns and Real-World Effect…
Feat.
M. Di
05:40
ASCO 2022 Conference Coverage
ASCO 2022 Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma: Re…
Feat.
P. Jain
57
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 Brexucabtagene Autoleucel for R/R Mantle…
Feat.
P. Jain
13:49
Seema Bhat
Surveying BTKi-Related AEs in CLL: Cardiovascular Risk in Patients R…
11:39
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)
SOHO 2021 Data on the Resistance to BTKi in CLL
Feat.
J. Woyach
09:11
Constantine Tam
SOHO 2021 Update on Resistance Mechanism to BCL-2 Inhibitors in CLL:…
15:54
Penn Medicine Abramson Cancer Center
2021 ASCO Updates on Lymphoma and CLL
Feat.
J. Gerson
15:12
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
63 y/o Male With MCL: What Initial Therapy to Choose? What Would Be …
Feat.
A. Duvall,
P. Riedell,
B. Derman,
S. Kosuri
19:43
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights on R/R MCL: The Role of BTKis, CAR-T, and Chemothera…
Feat.
J. Cohen
18:11
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)
SOHO 2021 Highlights on the Use of MRD in CLL: American Perspective
Feat.
M. Davids
15:32
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)
2021 SOHO Update on Dissecting the Biology of MCL: What Is Clinicall…
Feat.
T. Witzig
21:44
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on Efficacy and AE Management of BTKi in CLL/SLL
Feat.
J. Rhodes
11:06
ASH 2021 Conference Coverage on VuMedi
ASH 2021 MRD Assessment in CLL
Feat.
P. Ghia
10:24
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)
SOHO 2021 Highlights on Optimal Treatment of MCL: Future Strategies
Feat.
M. Dreyling
